Latest filings (excl ownership)
15-12G
Securities registration termination
26 Apr 23
8-K
Entry into a Material Definitive Agreement
11 Apr 23
10-K
2022 FY
Annual report
31 Mar 23
EFFECT
Notice of effectiveness
30 Mar 23
EFFECT
Notice of effectiveness
30 Mar 23
EFFECT
Notice of effectiveness
30 Mar 23
EFFECT
Notice of effectiveness
30 Mar 23
EFFECT
Notice of effectiveness
30 Mar 23
EFFECT
Notice of effectiveness
30 Mar 23
EFFECT
Notice of effectiveness
30 Mar 23
POS AM
Prospectus update (post-effective amendment)
28 Mar 23
POS AM
Prospectus update (post-effective amendment)
28 Mar 23
POS AM
Prospectus update (post-effective amendment)
28 Mar 23
POS AM
Prospectus update (post-effective amendment)
28 Mar 23
POS AM
Prospectus update (post-effective amendment)
28 Mar 23
POS AM
Prospectus update (post-effective amendment)
28 Mar 23
POS AM
Prospectus update (post-effective amendment)
28 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
28 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
28 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
28 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
28 Mar 23
25
Voluntary exchange delisting
27 Mar 23
8-K
Other Events
22 Mar 23
8-K
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange
15 Mar 23
8-K
ObsEva Announces Update Towards its Strategic Reorganization to Consolidate Operations in Switzerland
13 Mar 23
8-K
Entry into a Material Definitive Agreement
1 Mar 23
8-K
ObsEva Announces Strategic Reorganization to Consolidate Operations in Switzerland
24 Feb 23
8-K
Regulation FD Disclosure
3 Jan 23
6-K
ObsEva Announces Dismissal of Moratorium Proceedings
19 Dec 22
6-K
ObsEva Evidences Compliance with Nasdaq’s Stockholder’s Equity Rule and Announces Moratorium Dismissal Request Filing
14 Dec 22
EFFECT
Notice of effectiveness
13 Dec 22
6-K
ObsEva To Increase Issued Share Capital by Creating Additional Treasury Shares
9 Dec 22
F-3
Shelf registration (foreign)
9 Dec 22
CORRESP
Correspondence with SEC
9 Dec 22
UPLOAD
Letter from SEC
9 Dec 22
6-K
Index to Unaudited Condensed Consolidated Financial Statements
1 Dec 22
6-K
Consent and Amendment Agreement
22 Nov 22
6-K
ObsEva Announces Progress on Cost Reduction Initiatives and Stay of
26 Oct 22
6-K
ObsEva Announces IND Approval for Yuyuan Bioscience’s Phase 1 Clinical Trial of Nolasiban in China
13 Oct 22
6-K
ObsEva Announces Progress on Restructuring Initiatives
13 Sep 22
Latest ownership filings
SC 13D
Loumaye Ernest
17 Apr 23
4
Ernest Loumaye
11 Apr 23
4
Ernest Loumaye
2 Mar 23
4
William Michael Brown
24 Feb 23
SC 13G/A
Loumaye Ernest
14 Feb 23
3/A
Ernest Loumaye
14 Feb 23
SC 13D/A
Sofinnova Venture Partners VIII, L.P.
6 Feb 23
3
Edward T Mathers
3 Jan 23
3
Catarina Edfjall
3 Jan 23
3
ANNE VANLENT
3 Jan 23
3
Annette Clancy
3 Jan 23
3
BRIAN O'CALLAGHAN
3 Jan 23
3
Stephanie Clare Brown
3 Jan 23
3
William Michael Brown
3 Jan 23
3
Ernest Loumaye
3 Jan 23
SC 13D/A
Sofinnova Venture Partners VIII, L.P.
28 Feb 22
SC 13G/A
Loumaye Ernest
14 Feb 22
SC 13D/A
Sofinnova Venture Partners VIII, L.P.
4 Mar 21
SC 13G/A
ARMISTICE CAPITAL, LLC
16 Feb 21
SC 13G/A
Loumaye Ernest
16 Feb 21
SC 13G/A
ORBIMED ADVISORS LLC
12 Feb 21
SC 13G/A
Medicxi Growth I LP
11 Feb 21
SC 13G
ARMISTICE CAPITAL, LLC
14 Sep 20
SC 13G/A
Beneficial ownership report (amended)
14 Feb 20
SC 13G/A
Beneficial ownership report (amended)
14 Feb 20
SC 13D/A
ObsEva SA
13 Feb 20
SC 13G/A
ObsEva SA
14 Feb 19
SC 13G/A
ObsEva SA
14 Feb 19
SC 13G/A
ObsEva SA
14 Feb 19
SC 13G/A
ObsEva SA
12 Feb 19
SC 13G/A
ObsEva SA
5 Oct 18
SC 13G
ObsEva SA
14 Feb 18
SC 13G
ObsEva SA
14 Feb 18
SC 13G/A
ObsEva SA
14 Feb 18
SC 13G/A
ObsEva SA
14 Feb 18
SC 13G/A
ObsEva SA
13 Feb 18
SC 13G
ObsEva SA
1 Feb 18
SC 13G/A
ObsEva SA
22 Jan 18
SC 13G
ObsEva SA
26 Oct 17
SC 13D/A
ObsEva SA
19 Oct 17